Household transmission of COVID19 in Costa Rica

NIH Pandemic-Era Grants

Pandemic Era Grants

2021

↗ Live URL (may be dead)

Document text

Principal Investigator: D. Rebecca  Prevots
Organization: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
Fiscal Year: 2021
Award: $107,030
Funding agency: National Institute of Allergy and Infectious Diseases

Enrollment in this study has been completed, with 1023 persons enrolled in 304 households, for an average household size of 3.4 persons per household.  Preparation is underway to ship the samples to NIAID for IgG antibody testing.   Households eligible for selection were those with at least one other household member besides the index case.  After administration of the informed consent, epidemiologic and clinical data was obtained by interview or retrieved from medical records For each individual enrolled, information was obtained including 1) intensity and duration of exposure to index cases;  2) Use of preventive measures such as masks, 3) history of potential exposures outside of the home;  4) duration of quarantine as applicable;  4)  history of underlying medical conditions that have been associated with disease development, 5) history of signs and symptoms compatible with COVID19, since onset in the index case.   For each household, we also obtained information related to crowding and socioeconomic status.

Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><7S Gamma Globulin><Active Follow-up><Age><Americas><Antibodies><Antibody Response><Blood Sample><Blood specimen><COVID crisis><COVID epidemic><COVID infected patient><COVID pandemic><COVID patient><COVID positive patient><COVID-19><COVID-19 antibody><COVID-19 crisis><COVID-19 epidemic><COVID-19 global health crisis><COVID-19 global pandemic><COVID-19 health crisis><COVID-19 infected patient><COVID-19 pandemic><COVID-19 patient><COVID-19 positive patient><COVID-19 public health crisis><COVID-19 transmission><COVID-19 virus><COVID-19 virus transmission><COVID19><COVID19 crisis><COVID19 epidemic><COVID19 global health crisis><COVID19 global pandemic><COVID19 health crisis><COVID19 pandemic><COVID19 patient><COVID19 positive patient><COVID19 public health crisis><COVID19 virus><CV-19><CV19><Cancers><Cervical><Clinical><Clinical Data><CoV-2><CoV2><Collaborations><Complex><Costa Rica><Costa Rican><Crowding><Development><Diagnostic Findings><Disease><Disorder><Enrollment><Epidemiological data><Epidemiology data><Exposure to><Goals><HPV Vaccine><Health Care Systems><Healthcare Systems><History><Home><Household><Human Papilloma Virus Vaccine><Human papillomavirus Vaccine><IgA><IgG><Immune response><Immunoglobulin A><Immunoglobulin G><Immunological response><Immunology><Individual><Infection><Informed Consent><Infrastructure><Interview><Malignant Neoplasms><Malignant Tumor><Masks><Medical><Medical Records><NCI Organization><NIAID><National Cancer Institute><National Institute of Allergy and Infectious Disease><Patient Self-Report><Persons><Preparation><Preventative measure><Preventive measure><Prospective Studies><Quarantine><Randomization trial><Recording of previous events><Research><Research Institute><Risk Factors><SARS corona virus 2><SARS-CoV-2><SARS-CoV-2 antibody><SARS-CoV-2 epidemic><SARS-CoV-2 global health crisis><SARS-CoV-2 global pandemic><SARS-CoV-2 infected patient><SARS-CoV-2 pandemic><SARS-CoV-2 patient><SARS-CoV-2 positive patient><SARS-CoV-2 transmission><SARS-CoV2><SARS-CoV2 antibody><SARS-CoV2 epidemic><SARS-CoV2 pandemic><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 epidemic><SARS-coronavirus-2 pandemic><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Sampling><Self-Report><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 epidemic><Severe Acute Respiratory Syndrome CoV 2 pandemic><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 epidemic><Severe acute respiratory syndrome coronavirus 2 pandemic><Severe acute respiratory syndrome related corona virus 2><Ships><Signs and Symptoms><Socio-economic status><Socioeconomic Status><Transmission><Vaccines><Viral><Wuhan coronavirus><active followup><ages><antibody against COVID-19><antibody against SARS-CoV-2><antibody against SARS-CoV2><antibody against coronavirus disease 2019><antibody against severe acute respiratory syndrome coronavirus 2><antibody based test><antibody test><antibody to COVID-19><antibody to SARS-CoV-2><antibody to SARS-CoV2><antibody to coronavirus disease 2019><antibody to severe acute respiratory syndrome coronavirus 2><cohort><corona virus disease 2019><corona virus disease 2019 epidemic><corona virus disease 2019 pandemic><coronavirus disease 2019><coronavirus disease 2019 antibody><coronavirus disease 2019 crisis><coronavirus disease 2019 epidemic><coronavirus disease 2019 global health crisis><coronavirus disease 2019 global pandemic><coronavirus disease 2019 health crisis><coronavirus disease 2019 infected patient><coronavirus disease 2019 pandemic><coronavirus disease 2019 patient><coronavirus disease 2019 positive patient><coronavirus disease 2019 public health crisis><coronavirus disease 2019 transmission><coronavirus disease 2019 virus><coronavirus disease 2019 virus transmission><coronavirus disease crisis><coronavirus disease epidemic><coronavirus disease infected patient><coronavirus disease pandemic><coronavirus disease patient><coronavirus disease positive patient><coronavirus patient><developmental><enroll><epidemiologic data><follow up><follow-up><followed up><followup><hCoV19><host response><immune system response><immunoresponse><indexing><infection rate><isolation/quarantine><malignancy><member><nCoV2><neoplasm/cancer><patient infected with COVID><patient infected with COVID-19><patient infected with SARS-CoV-2><patient infected with coronavirus disease><patient infected with coronavirus disease 2019><patient infected with severe acute respiratory syndrome coronavirus 2><patient with COVID><patient with COVID-19><patient with COVID19><patient with SARS-CoV-2><patient with coronavirus disease><patient with coronavirus disease 2019><patient with severe acute respiratory distress syndrome coronavirus 2><primary end point><primary endpoint><protective efficacy><randomized trial><rate of infection><secondary infection><severe acute respiratory syndrome coronavirus 2 antibody><severe acute respiratory syndrome coronavirus 2 global health crisis><severe acute respiratory syndrome coronavirus 2 global pandemic><severe acute respiratory syndrome coronavirus 2 infected patient><severe acute respiratory syndrome coronavirus 2 patient><severe acute respiratory syndrome coronavirus 2 positive patient><severe acute respiratory syndrome coronavirus 2 transmission><sex><socio-economic position><socioeconomic position><transmission process><transmitted COVID-19><transmitted SARS-CoV-2><transmitted coronavirus disease 2019><transmitted severe acute respiratory syndrome coronavirus 2>